BioSpace News Archive

Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ

TUKYSA Combination Reduced Risk of Cancer Progression in the Brain or Death by Two-Thirds, Doubled Response Rate and Reduced Risk of Death by Nearly Half Compared to Standard Therapy Alone - - Published Simultaneously in the Journal of Clinical Oncology and Presented in an Oral Session During the Virtual Scientific Program of the 2020 ASCO Annual Meeting - - First Anti-HER2 Oral Therapy in Combination with Standard Medicines to Improve Overall

Poster Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting Highlights TPX-0046 Potent Inhibition of Wildtype RET and RET Mutations

ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) from its ongoing Phase 1/2 study of GB1275 in patien

IMFINZI ® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial ASCO data show more than 10% of patients on IMFINZI plus chemotherapy had not progressed and remained on treatment at two years vs. 2.9% on chemotherapy alone WILMINGTON, Del.--( BUSINESS WIRE )-- Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s IMFINZI in comb

HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an upcoming presentation, entitled Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation, showing data from the open-label treatment protocol with mavrilimumab, an

- Positive data presented at ASCO follows announcement of Fast Track Designation granted by the FDA for onvansertib in second-line treatment of patients with KRAS-mutated mCRC - 89% overall clinical benefit achieved - objective response rate (ORR) of 44% (4 of 9 evaluable patients as of ASCO cutoff) - One additional objective response achieved post ASCO reporting - ORR of 45% (5 of 11 evaluable patients) - Data continues to demonstrate a ten-fold ORR over curren

Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid [29-May-2020] SAN DIEGO , May 29, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa

Nano DiagnosiX ( https://www.nanodiagnosix.com/ ) recently announced the development of FemtoSpot, a biosensor made through a proprietary manufacturing process that creates nanostructure-based, field-effect tra